The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
An oral preparation of picoplatin, a third generation platinum compound
with antineoplastic activity. Designed to overcome platinum drug
resistance, picoplatin alkylates DNA, forming both inter- and
intra-strand cross-linkages, resulting in inhibition of DNA replication
and RNA transcription and the induction of apoptosis.
Because of the increase in steric bulk around the platinum center,
there is a relative reduction in the inactivation of picoplatin by
species such as glutathione and metallothionein in comparison to